Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1993 • 28,274 citations

Cochrane Handbook for Systematic Reviews of Interventions

2008 • 18,785 citations

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

2002 • 12,876 citations

Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)

2002 • 12,292 citations

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

2002 • 9,810 citations

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

2012 • 8,436 citations

2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults

2013 • 7,509 citations

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

2013 • 6,963 citations

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

1998 • 6,576 citations

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

1998 • 5,793 citations

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1997 • 5,689 citations

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

1998 • 4,813 citations

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)

2007 • 3,757 citations

The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1997 • 3,652 citations

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy

2000 • 3,103 citations

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

2001 • 3,093 citations

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension

1997 • 2,965 citations

Treatment of Hypertension in Patients 80 Years of Age or Older

2008 • 2,927 citations

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

2009 • 2,611 citations

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

2012 • 2,501 citations

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

2003 • 2,365 citations

European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

2003 • 2,264 citations

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

2003 • 2,138 citations

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

2007 • 1,978 citations

Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)

2007 • 1,649 citations

EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE

2005 • 1,314 citations

The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension

1998 • 1,166 citations

Preventing Microalbuminuria in Type 2 Diabetes

2004 • 1,000 citations

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

2002 • 848 citations

The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

2015 • 685 citations

Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events

2000 • 671 citations

Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria

2004 • 510 citations

Management of hypertension: summary of NICE guidance

2011 • 465 citations

Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk

2005 • 453 citations

'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). [Eur Heart J 2012;33:1635-1701, doi: 10.1093/eurheartj/…

2012 • 411 citations

Prediction of benefit from carotid endar terectomy in individual patients: a risk-modelling study

1999 • 396 citations

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

2007 • 396 citations

Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk

2005 • 324 citations

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)

2004 • 286 citations

Management of raised blood pressure in New Zealand: a discussion document.

1993 • 270 citations

Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis

2000 • 268 citations

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease

2000 • 236 citations

Updated New Zealand cardiovascular disease risk-benefit prediction guide

2000 • 235 citations

The Effects of Blood Pressure Reduction in Older Patients: An Overview of Five Randomized Controlled Trials in Elderly Hypertensives

1993 • 191 citations

The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

2013 • 166 citations

Estimating treatment effects for individual patients based on the results of randomised clinical trials

2011 • 154 citations

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand

2005 • 144 citations

Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa

2005 • 143 citations

Individualized Guidelines: The Potential for Increasing Quality and Reducing Costs

2011 • 136 citations

Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments

1998 • 96 citations

Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance

2008 • 91 citations

Selection of thrombolytic therapy for individual patients: Development of a clinical model

1997 • 85 citations

The influence of absolute cardiovascular risk, patient utilities and costs on the decision to treat hypertension

2003 • 80 citations

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study

2012 • 68 citations

The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension

2003 • 67 citations

An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase

2002 • 61 citations

Tight Versus Standard Blood Pressure Control in Patients With Hypertension With and Without Cardiovascular Disease

2013 • 36 citations

Deleted Work

1955 • 0 citations